MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular options as drug targets and antibody-drug conjugates for remedy
Superior colorectal adenocarcinoma (CRAC), featured by distinctive histopathological look, distant organ metastasis, acquired chemoresistance, and tumorigenic stemness is a bunch of heterogeneous cancers with distinctive genetic signatures and malignant phenotypes. Remedy of CRAC is a daunting exercise for oncologists.
In the mean time, quite a few strategies along with molecular specializing in using therapeutic monoclonal antibodies, small molecule kinase inhibitors and immunoregulatory checkpoint treatment have been utilized to battle this deadly sickness. Nonetheless, these therapeutic modalities and approaches receive solely restricted success. Thus, there is a pharmaceutical wish to discover new targets and develop novel therapeutics for CRAC treatment. MET and RON receptor tyrosine kinases have been implicated in CRAC pathogenesis.
Scientific analysis have revealed that aberrant MET and/or RON expression and signaling are important in regulating CRAC improvement and malignant phenotypes. Elevated MET and/or RON expression moreover has prognostic price for CRAC improvement and affected individual survival.
These choices current the rationale to give attention to MET and RON for scientific CRAC intervention. At present, utilizing small molecule kinase inhibitors specializing in MET for CRAC remedy has achieved very important progress with plenty of approvals for scientific utility.
Nonetheless, antibody-based biotherapeutics, although beneath scientific trials for better than Eight years, have made little or no progress. On this evaluation, we give attention to the importance of MET and/or RON in CRAC tumorigenesis and development of anti-MET, anti-RON, and MET and RON-dual specializing in antibody-drug conjugates for scientific utility. The findings from every preclinical analysis and scientific trials highlight the potential of this novel sort of biotherapeutics for CRAC treatment in the end.
Antibody Response to Canine Parvovirus Vaccination in Canines with Hyperadrenocorticism Dealt with with Trilostane
- It is unknown how canines with hyperadrenocorticism (HAC) reply to vaccination. This analysis measured antibodies in opposition to canine parvovirus (CPV) in canines with HAC dealt with with trilostane sooner than and after CPV vaccination, and in distinction the immune response to that from healthful canines. Eleven canines with HAC, and healthful age-matched administration canines (n = 31) obtained a modified-live CPV vaccine. Antibodies have been selected days 0, 7, and 28 by hemagglutination inhibition. Univariate analysis was used to match the immune response of canines with HAC and healthful canines.
- Pre-vaccination antibodies (≥10) have been detected in 100% of canines with HAC (11/11; 95% CI: 70.0-100) and in 93.5% of healthful canines (29/31; 95% CI: 78.3-99.2). No ≥4-fold improve in antibody titer was observed in canines with HAC whereas in 22.6% of healthful canines, a ≥4-fold titer improve was observed (7/31; 95% CI: 11.1-40.1).
- Light vaccine-associated antagonistic events (VAAEs) have been detected in 54.5% of canines with HAC (6/11; 95% CI: 28.0-78.8) and in 29.0% of healthful canines (9/31; 95% CI: 15.9-46.8). There was neither a very important distinction in presence of pre-vaccination antibodies (p = 1.000), or response to vaccination (p = 0.161), nor inside the prevalence of VAAEs (p = 0.158). Immune carry out of canines with HAC dealt with with trilostane seems much like that of healthful canines.
Design and Validation of Linkers for Web site-Explicit Preparation of Antibody-Drug Conjugates Carrying A variety of Drug Copies Per Cysteine Conjugation Web site
First-generation cysteine-based site-specific antibody-drug conjugates (ADCs) are restricted to 1 drug per cysteine. Nonetheless, certain functions require a extreme drug to antibody ratio (DAR), comparable to when low-potency payloads are used. Elevated drug load could also be achieved using classical cysteine conjugation methods, nevertheless these result in heterogeneity, suboptimal efficacy and pharmacokinetics.
Proper right here, we describe the design, synthesis and validation of heterobifunctional linkers that may be utilized for the preparation of ADCs with a DAR of two, three and Four in a site-specific methodology per single cysteine conjugation web site, resulting in site-specific ADCs with a DAR of 4, six and eight. The designed linkers carry a sulfhydryl-specific iodoacetyl reactive group, and plenty of cyclic diene moieties which could successfully react with maleimide-carrying payloads by way of the Diels-Alder response.
As a proof of concept, we synthesized site-specific DAR 4, six and eight ADCs carrying tubulysin (AZ13601508) using engineered antibodies with a cysteine inserted after place 239 inside the antibody CH2 space.
We evaluated and in distinction the in vitro cytotoxicity of ADCs obtained by means of the site-specific platform described herein, with ADCs prepared using classical cysteine conjugation. Our data validated a novel cysteine-based conjugation platform for the preparation of site-specific ADCs with extreme drug load for therapeutic functions.
Supplier Antibody Serology Research of Virus within the Emergency Room (PASSOVER) Research: Particular Inhabitants COVID-19 Seroprevalence
Introduction: Restricted information on the seroprevalence of extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amongst healthcare staff (HCW) are publicly accessible. On this research we sought to find out the seroprevalence of SARS-CoV-2 in a inhabitants of HCWs in a pediatric emergency division (ED).
Strategies: We performed this observational cohort research from April 14-Might 13, 2020 in a pediatric ED in Orange County, CA. Asymptomatic HCW ≥18 years of age had been included within the research. Blood samples had been obtained by fingerstick firstly of every shift. The inter-sampling interval was ≤96 hours. The first end result was optimistic seroprevalence of SARS-CoV-2 as decided with an antibody quick detection equipment (Colloidal Gold, Superbio, Timisoara, Romania) for the SARS-CoV-2 immunoglobulin M/immunoglobulin G (IgM/IgG) antibody.
Outcomes: A complete of 143 HCWs participated within the research. General SARS-CoV-2 seroprevalence was 10.5% (n = 15). Optimistic seroprevalence was categorised as IgG solely (4.9%), IgM+IgG (3.5%), or IgM solely (2.1%). SARS-CoV-2 was detected by reverse transcription polymerase chain response RT-PCR in 0.7% of the general research inhabitants (n = 1). Samples obtained on Day 1 indicated seropositivity in 4.2% of the research inhabitants (n = 6). Subsequent seroconversion occurred in 6.3% of individuals (n = 9). The speed of seroconversion was linear with a price of roughly one new case each two days, beginning at Day 9 of the research.
Conclusion: We noticed a linear price of seroconversion to SARS-CoV-2-positive standing amongst asymptomatic HCWs who underwent every day symptom surveys and temperature screens in an atmosphere with common supply management. Speedy antibody testing could also be helpful for screening for SARS-CoV-2 seropositivity in high-risk populations, reminiscent of HCWs within the ED.
Cluster Percolation Causes Shear Thinning Habits in Concentrated Options of Monoclonal Antibodies
Excessive-concentration (>100 g/L) options of monoclonal antibodies (mAbs) are sometimes characterised by anomalously massive resolution viscosity and shear thinning conduct for pressure charges ≥103 s-1. Right here, the hyperlink between protein-protein interactions (PPIs) and the rheology of concentrated options of COE-03 and COE-19 mAbs is studied via static and dynamic mild scattering and microfluidic rheometry. By evaluating the experimental information with predictions based mostly on the Baxter sticky hard-sphere mannequin, we surprisingly discover a connection between the noticed shear thinning and the expected percolation threshold.
The longest shear leisure time of mAbs was a lot bigger than that of mannequin sticky laborious spheres inside the identical area of the section diagram, which is attributed to the anisotropy of the mAb PPIs. Our outcomes counsel that not solely the energy but in addition the patchiness of short-range engaging PPIs needs to be explicitly accounted for by theoretical approaches aimed toward predicting the shear rate-dependent viscosity of dense mAb options.
Calcitonin (CT) Monoclonal Antibody (Human) | |||
4-MAA472Hu22 | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT) |
Calcitonin (CT) Monoclonal Antibody (Rat), PE | |||
4-MAA472Ra21-PE | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with PE. |
Calcitonin (CT) Monoclonal Antibody (Rat), APC | |||
4-MAA472Ra21-APC | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with APC. |
Calcitonin (CT) Monoclonal Antibody (Rat), Cy3 | |||
4-MAA472Ra21-Cy3 | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with Cy3. |
Calcitonin (CT) Monoclonal Antibody (Rat), HRP | |||
4-MAA472Ra21-HRP | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with HRP. |
Calcitonin (CT) Monoclonal Antibody (Human), PE | |||
4-MAA472Hu22-PE | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with PE. |
Calcitonin (CT) Monoclonal Antibody (Rat), FITC | |||
4-MAA472Ra21-FITC | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with FITC. |
Calcitonin (CT) Monoclonal Antibody (Human), APC | |||
4-MAA472Hu22-APC | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with APC. |
Calcitonin (CT) Monoclonal Antibody (Human), Cy3 | |||
4-MAA472Hu22-Cy3 | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with Cy3. |
Calcitonin (CT) Monoclonal Antibody (Human), HRP | |||
4-MAA472Hu22-HRP | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with HRP. |
Calcitonin (CT) Monoclonal Antibody (Human), FITC | |||
4-MAA472Hu22-FITC | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with FITC. |
monoclonal anti-Human Calcitonin (CT) IgG | |||
CT12-M | Alpha Diagnostics | 100 ug | EUR 578.4 |
Calcitonin (CT) Monoclonal Antibody (Rat), Biotinylated | |||
4-MAA472Ra21-Biotin | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with Biotin. |
Mouse Anti Human Calcitonin Monoclonal Antibody | |||
CABT-49104MH | Creative Diagnostics | 0.2 mg | EUR 852 |
Calcitonin (CT) Monoclonal Antibody (Rat), APC-Cy7 | |||
4-MAA472Ra21-APC-Cy7 | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Rat Calcitonin (CT). This antibody is labeled with APC-Cy7. |
Calcitonin (CT) Monoclonal Antibody (Human), Biotinylated | |||
4-MAA472Hu22-Biotin | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with Biotin. |
Calcitonin (CT) Monoclonal Antibody (Human), APC-Cy7 | |||
4-MAA472Hu22-APC-Cy7 | Cloud-Clone |
|
|
Description: A Mouse monoclonal antibody against Human Calcitonin (CT). This antibody is labeled with APC-Cy7. |
monoclonal anti-Human Calcitonin (CT) IgG #2 | |||
CT13-M | Alpha Diagnostics | 100 ug | EUR 578.4 |
Mouse Anti Rat Calcitonin Receptor Monoclonal Antibody | |||
CABT-49691MR | Creative Diagnostics | 0.1 mg | EUR 1070.4 |
Mouse Anti Human Calcitonin Receptor Monoclonal Antibody | |||
CABT-48598MH | Creative Diagnostics | 0.1 mg | EUR 920.4 |
Mouse Anti Human Calcitonin Receptor Monoclonal Antibody | |||
CABT-48599MH | Creative Diagnostics | 0.1 mg | EUR 920.4 |
Calcitonin (Calcitonin (CALCA)) mouse monoclonal antibody, clone OTI2F5 (formerly 2F5) | |||
TA190005 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 42 | |||
4PC47-42 | Origene Technologies GmbH | 1 mg | Ask for price |
Mouse Anti-Human Calcitonin monoclonal antibody, clone JID632 | |||
CABT-L2980-100uL500uL | Creative Diagnostics | 100 uL, 500 uL | EUR 602.4 |
Mouse Anti-Human Calcitonin monoclonal antibody, clone JID632 | |||
CABT-L2980 | Creative Diagnostics | 100 µl, 500 µl | Ask for price |
Description: Mouse |
Calcitonin (CALCA) mouse monoclonal antibody, clone 13B9 | |||
4C10-13B9 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 13F2 | |||
4C10-13F2 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 14A2 | |||
4C10-14A2 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 16B5 | |||
4C10-16B5 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 24B2 | |||
4C10-24B2 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 18B7 | |||
4PC47-18B7 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 27A3 | |||
4PC47-27A3 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 44D9 | |||
4PC47-44D9 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 6F10 | |||
4PC47-6F10 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 13G11 | |||
4C10-13G11 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 14C12 | |||
4PC47-14C12 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 22A11 | |||
4PC47-22A11 | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone 38F11 | |||
4PC47-38F11 | Origene Technologies GmbH | 1 mg | Ask for price |
Mouse Anti Rat Calcitonin Receptor (C1b Isoform) Monoclonal Antibody | |||
CABT-49689MR | Creative Diagnostics | 0.1 mg | EUR 1070.4 |
Calcitonin (CALCA) (in vitro) mouse monoclonal antibody, clone 14A2cc | |||
4C10cc-14A2cc | Origene Technologies GmbH | 1 mg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI9H2 (formerly 9H2) | |||
TA190009 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI2H3 (formerly 2H3) | |||
TA190010 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI3F6 (formerly 3F6) | |||
TA190012 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI11H8 (formerly 11H8) | |||
TA190006 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI2D10 (formerly 2D10) | |||
TA190007 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI11G4 (formerly 11G4) | |||
TA190008 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI2D12 (formerly 2D12) | |||
TA190011 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone OTI2A12 (formerly 2A12) | |||
TA190013 | Origene Technologies GmbH | 100 µl | Ask for price |
Calcitonin receptor (CALCR) mouse monoclonal antibody, clone 31/01, Purified | |||
SM1868P | Origene Technologies GmbH | 100 µg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone Cn11 (BGN/1199/11), Aff - Purified | |||
BM920 | Origene Technologies GmbH | 200 µg | Ask for price |
Calcitonin (CALCA) mouse monoclonal antibody, clone Cn44 (BGN/1199/44), Aff - Purified | |||
BM921 | Origene Technologies GmbH | 200 µg | Ask for price |
Rabbit monoclonal antibody against Calcitonin(clone EPR68(2)) | |||
TA307516 | Origene Technologies GmbH | 100 µl | Ask for price |
Monoclonal CALCR / Calcitonin Receptor Antibody (clone 2F7), Clone: 2F7 | |||
AMM02230G | Leading Biology | 0.05mg | EUR 633.6 |
Description: A Monoclonal antibody against Human CALCR / Calcitonin Receptor (clone 2F7). The antibodies are raised in Mouse and are from clone 2F7. This antibody is applicable in WB and IHC-P, E |
Monoclonal Calcitonin Gene Related Peptide (CGRP) Antibody, Clone: 4901 | |||
APR11543G | Leading Biology | 0.1ml | EUR 633.6 |
Description: A Monoclonal antibody against Human Calcitonin Gene Related Peptide (CGRP). The antibodies are raised in Mouse and are from clone 4901. This antibody is applicable in ICC |
Calcitonin (CT) Polyclonal Antibody (Mouse) | |||
4-PAA472Mu01 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT) |
Calcitonin (CT) Antibody | |||
20-abx100227 | Abbexa |
|
|
Calcitonin (CT) Antibody | |||
20-abx100228 | Abbexa |
|
|
Calcitonin (CT) Antibody | |||
20-abx100230 | Abbexa |
|
|
Calcitonin (CT) Antibody | |||
20-abx175651 | Abbexa |
|
|
Calcitonin (CT) Antibody | |||
20-abx171510 | Abbexa |
|
|
Calcitonin (CT) Antibody | |||
20-abx104916 | Abbexa |
|
|
Calcitonin (CT) Polyclonal Antibody (Mouse), PE | |||
4-PAA472Mu01-PE | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with PE. |
Calcitonin (CT) Polyclonal Antibody (Mouse), APC | |||
4-PAA472Mu01-APC | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with APC. |
Calcitonin (CT) Polyclonal Antibody (Mouse), Cy3 | |||
4-PAA472Mu01-Cy3 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with Cy3. |
Calcitonin (CT) Polyclonal Antibody (Mouse), HRP | |||
4-PAA472Mu01-HRP | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with HRP. |
Calcitonin (CT) Polyclonal Antibody (Mouse), FITC | |||
4-PAA472Mu01-FITC | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with FITC. |
Calcitonin (CT) Antibody (Biotin) | |||
20-abx271724 | Abbexa |
|
|
Calcitonin (CT) Antibody (Biotin) | |||
20-abx271988 | Abbexa |
|
|
Calcitonin (CT) Polyclonal Antibody (Mouse), Biotinylated | |||
4-PAA472Mu01-Biotin | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with Biotin. |
Calcitonin (CT) Polyclonal Antibody (Mouse), APC-Cy7 | |||
4-PAA472Mu01-APC-Cy7 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Mouse Calcitonin (CT). This antibody is labeled with APC-Cy7. |
Calcitonin (CT) Polyclonal Antibody | |||
CAU31077-100ul | Biomatik Corporation | 100ul | EUR 229.4 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU31077-200ul | Biomatik Corporation | 200ul | EUR 287.3 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU29927-100ul | Biomatik Corporation | 100ul | EUR 228.5 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU29927-200ul | Biomatik Corporation | 200ul | EUR 285.6 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU29928-100ul | Biomatik Corporation | 100ul | EUR 217.9 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU29928-200ul | Biomatik Corporation | 200ul | EUR 272.2 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU30282-100ul | Biomatik Corporation | 100ul | EUR 228.5 |
Calcitonin (CT) Polyclonal Antibody | |||
CAU30282-200ul | Biomatik Corporation | 200ul | EUR 285.6 |
Mouse Calcitonin (CT) ELISA | |||
KT-8857 | Kamiya Biomedical Company | 96 tests | EUR 977 |
Mouse Calcitonin (CT) Protein | |||
20-abx065656 | Abbexa |
|
|
Polyclonal Antibody to Calcitonin (CT) | |||
PAA472Ge01 | Cloud-Clone | 100ul | EUR 238 |
Polyclonal Antibody to Calcitonin (CT) | |||
PAA472Hu01 | Cloud-Clone | 100ul | EUR 238 |
Polyclonal Antibody to Calcitonin (CT) | |||
PAA472Hu02 | Cloud-Clone | 100ul | EUR 238 |
Polyclonal Antibody to Calcitonin (CT) | |||
PAA472Mu01 | Cloud-Clone | 100ul | EUR 227 |
Polyclonal Antibody to Calcitonin (CT) | |||
PAA472Ra01 | Cloud-Clone | 100ul | EUR 239 |
Calcitonin (CT) Polyclonal Antibody (Dog) | |||
4-PAA472Ca01 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Dog Calcitonin (CT) |
Calcitonin (CT) Polyclonal Antibody (Human) | |||
4-PAA472Hu01 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Human Calcitonin (CT) |
Calcitonin (CT) Polyclonal Antibody (Human) | |||
4-PAA472Hu02 | Cloud-Clone |
|
|
Description: A Rabbit polyclonal antibody against Human Calcitonin (CT) |
Mouse Calcitonin (CT) CLIA Kit | |||
abx196301-96tests | Abbexa | 96 tests | EUR 990 |
Mouse CT -Calcitonin- CLIA Kit | |||
E-CL-M0158-24Tests | Elabscience Biotech | 24 Tests | EUR 180 |
Description: Sandwich |
Mouse CT -Calcitonin- CLIA Kit | |||
E-CL-M0158-48Tests | Elabscience Biotech | 48 Tests | EUR 546 |
Description: Sandwich |
Mouse CT -Calcitonin- CLIA Kit | |||
E-CL-M0158-96Tests | Elabscience Biotech | 96 Tests | EUR 682 |
Description: Sandwich |
Mouse CT -Calcitonin- CLIA Kit | |||
E-CL-M0158-96Tests10 | Elabscience Biotech | 96 Tests *10 | EUR 6820 |
Description: Sandwich |
Mouse CT -Calcitonin- CLIA Kit | |||
E-CL-M0158-96Tests5 | Elabscience Biotech | 96 Tests *5 | EUR 3410 |
Description: Sandwich |
Mouse Calcitonin (CT) ELISA Kit | |||
DLR-CT-Mu | DL Develop | 96T | EUR 432 |
Description: serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |
Mouse Calcitonin (CT) ELISA Kit | |||
DLR-CT-Mu-48T | DL Develop | 48T | EUR 586.8 |
Description: A competitive inhibition quantitative ELISA assay kit for detection of Mouse Calcitonin (CT) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids. |